tiprankstipranks
Trending News
More News >
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
India Market
Advertisement

Glenmark Pharmaceuticals Limited (GLENMARK) Price & Analysis

Compare
2 Followers

GLENMARK Stock Chart & Stats


GLENMARK FAQ

What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1274.70 and its highest was ₹2286.15 in the past 12 months.
    What is Glenmark Pharmaceuticals Limited’s market cap?
    Glenmark Pharmaceuticals Limited’s market cap is ₹546.50B.
      When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
      Glenmark Pharmaceuticals Limited’s upcoming earnings report date is Nov 07, 2025 which is in 73 days.
        How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
        Glenmark Pharmaceuticals Limited released its earnings results on Aug 14, 2025. The company reported ₹1.66 earnings per share for the quarter, missing the consensus estimate of ₹12.9 by -₹11.24.
          Is Glenmark Pharmaceuticals Limited overvalued?
          According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Glenmark Pharmaceuticals Limited pay dividends?
            Glenmark Pharmaceuticals Limited pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 0.13%. See more information on Glenmark Pharmaceuticals Limited dividends here
              What is Glenmark Pharmaceuticals Limited’s EPS estimate?
              Glenmark Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Glenmark Pharmaceuticals Limited have?
              Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding.
                What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
                Glenmark Pharmaceuticals Limited reported an EPS of ₹1.66 in its last earnings report, missing expectations of ₹12.9. Following the earnings report the stock price went up 0.598%.
                  Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
                  Currently, no hedge funds are holding shares in IN:GLENMARK

                  Company Description

                  Glenmark Pharmaceuticals Limited

                  Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. It operates in the healthcare sector, focusing on the research, development, manufacture, and marketing of branded and generic formulations. Glenmark is involved in the therapeutic areas of dermatology, oncology, respiratory, and cardiovascular diseases. The company is known for its robust pipeline of new chemical entities and biosimilars, and it has a significant presence in both emerging and developed markets.

                  Glenmark Pharmaceuticals Limited (GLENMARK) Earnings & Revenues

                  GLENMARK Stock 12 Month Forecast

                  Average Price Target

                  ₹2,076.60
                  ▲(7.23% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1277":"₹1,277","1894":"₹1,894","2511":"₹2,511","1585.5":"₹1,585.5","2202.5":"₹2,202.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2510,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.51K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2076.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1277,1585.5,1894,2202.5,2511],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2066.95,2101.0307692307692,2135.111538461538,2169.1923076923076,2203.2730769230766,2237.353846153846,2271.4346153846154,2305.5153846153844,2339.596153846154,2373.6769230769232,2407.757692307692,2441.8384615384616,2475.9192307692306,{"y":2510,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2066.95,2067.6923076923076,2068.4346153846154,2069.176923076923,2069.9192307692306,2070.6615384615384,2071.403846153846,2072.1461538461535,2072.8884615384613,2073.630769230769,2074.373076923077,2075.1153846153843,2075.857692307692,{"y":2076.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2066.95,2023.3384615384614,1979.726923076923,1936.1153846153845,1892.503846153846,1848.8923076923077,1805.2807692307692,1761.6692307692306,1718.0576923076924,1674.4461538461537,1630.8346153846155,1587.2230769230769,1543.6115384615384,{"y":1500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1436.34,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1685.58,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1666.7,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1693.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1550,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1614.05,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1452.5,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1278.75,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1278.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1380.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1496.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1754.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2066.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alkem Laboratories Ltd.
                  Aurobindo Pharma Ltd
                  Biocon Limited
                  GlaxoSmithKline Pharmaceuticals Limited
                  Lupin Limited
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis